WHA releases new messaging guide for global fund advocates

For the past 18 months, WHA and partners have been advocating for the Global Fund to include more support for hepatitis services within their funding remit.

The Global Fund is currently developing its new strategy for the period 2023 -2028. To develop the strategy a series of virtual partnership forums are taking place to get input from Global Fund stakeholders. It is vital that we have supportive voices for the inclusion of hepatitis within the new strategy at the forums. 

WHA has created a new advocacy messaging briefing which highlights our ask for the inclusion of hepatitis services within the next Global Fund strategy 

Download the guide here 

The partnership forums are being attended by advocates from the HIV, tuberculosis and malaria communities so if you’re organisation is not directly participating in the partnership forums then reaching out to national organisations working within those areas would be advantageous as we seek allies to join our call. 

  • Partnership Forum I: Eastern Europe and Central Asia & Latin America and the Caribbean 9-11 February 2021
  • Partnership Forum II: Africa & MENA I*, 17-19 February 2021
  • Partnership Forum III: East Asia Pacific, South West Asia & MENA II**, 3-5 March 2021

    *MENA I: includes Morocco, Egypt, Djibouti, Sudan, Somalia Tunisia, South Sudan, Algeria, Mauritania, Djibouti, Eritrea
    **MENA II: includes Iraq, Syria, Jordan, Lebanon, Yemen, Palestine. 

With your support, we are optimistic that we can obtain more support services for the millions of people living with viral hepatitis in countries supported by the Global Fund. 

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close